• 1-800-526-8630U.S. (TOLL FREE)
  • 1-917-300-0470EAST COAST U.S.
  • +353-1-416-8900REST OF WORLD
Herbert Irving Comprehensive Cancer Center - Product Pipeline Review - Q4 2010 Product Image

Herbert Irving Comprehensive Cancer Center - Product Pipeline Review - Q4 2010

  • ID: 1446572
  • December 2010
  • 135 pages
  • GlobalData

Herbert Irving Comprehensive Cancer Center – Product Pipeline Review – Q4 2010

Summary

Global Market Direct’s pharmaceuticals report, “Herbert Irving Comprehensive Cancer Center – Developmental Therapeutics Review – Q4 2010” provides data on the institute’s research and development focus. The report includes information on therapeutics under development, complete with latest updates, and features on discontinued projects (if applicable).

This report is built using data and information sourced from Global Markets Direct’s proprietary databases, institute’s website, and featured press releases, both from institute and industry-specific third party sources, put together by Global Markets Direct’s team of industry experts.

Scope

- Review of therapeutics under development by Herbert Irving Comprehensive Cancer Center.
- Overview of products under development across various therapy areas.
- Coverage of therapeutic molecules in various stages of drug development, including the combination treatment modalities, across the globe.
- Product profiles for late stage and clinical stage READ MORE >



List of Tables
List of Figures
Herbert Irving Comprehensive Cancer Center Snapshot
Herbert Irving Comprehensive Cancer Center Overview
Key Information
Key Facts
Herbert Irving Comprehensive Cancer Center – Research and Development Overview
Key Therapeutic Areas
Herbert Irving Comprehensive Cancer Center – Pipeline Review
Pipeline Products by Stage of Development
Pipeline Products – Monotherapy
Pipeline Products – Combination Treatment Modalities
Herbert Irving Comprehensive Cancer Center – Pipeline Products Glance
Herbert Irving Comprehensive Cancer Center – Late Stage Pipeline
Phase III Products/Combination Treatment Modalities
Herbert Irving Comprehensive Cancer Center Clinical Stage Pipeline Products
Phase II Products/Combination Treatment Modalities
Phase I Products/Combination Treatment Modalities
Herbert Irving Comprehensive Cancer Center – Drug Profiles
aldesleukin + recombinant interferon gamma + carboplatin + cyclophosphamide + cyclosporine + thiotepa
Product Description
Mechanism of Action
R&D Progress
Aldesleukin for Breast Cancer
Product Description
Mechanism of Action
R&D Progress
Carboplatin+Cyclophosphamide+Thiotepa
Product Description
Mechanism of Action
R&D Progress
Cyclosporine + Interferon Gamma
Product Description
Mechanism of Action
R&D Progress
Zoledronate
Product Description
Mechanism of Action
R&D Progress
aldesleukin + filgrastim + busulfan + cyclophosphamide + etoposide + melphalan
Product Description
Mechanism of Action
R&D Progress
ALVAC-CEA-B7.1 vaccine + tetanus toxoid + FOLFIRI regimen
Product Description
Mechanism of Action
R&D Progress
ALVAC-CEA/B7.1 + Tetanus toxoid + Irinotecan + Fluorouracil + Leucovorin
Product Description
Mechanism of Action
R&D Progress
Anti-Thymocyte Globulin + Cyclosporine + Fludarabine + Melphalan + Methylprednisolone + Mycophenolate Mofetil + Allogeneic Bone Marrow Transplantation/Peripheral Blood Stem Cell Transplantation/Syngeneic Bone Marrow Transplantation
Product Description
Mechanism of Action
R&D Progress
anti-thymocyte globulin + cyclosporine + fludarabine phosphate + melphalan + methylprednisolone + mycophenolate mofetil
Product Description
Mechanism of Action
R&D Progress
Cisplatin + Carboplatin + Gemcitabine
Product Description
Mechanism of Action
R&D Progress
docetaxel + carboplatin
Product Description
Mechanism of Action
R&D Progress
Docetaxel + Estramustine Phosphate
Product Description
Mechanism of Action
R&D Progress
docetaxel + estramustine phosphate sodium
Product Description
Mechanism of Action
R&D Progress
Doxil + Melphalan + Velcade
Product Description
Mechanism of Action
R&D Progress
Filgrastim + Carboplatin + Etoposide + Ifosfamide + Paclitaxel
Product Description
Mechanism of Action
R&D Progress
Filgrastim + Carboplatin + Etoposide + Ifosfamide + Paclitaxel
Product Description
Mechanism of Action
R&D Progress
filgrastim + carboplatin + etoposide + paclitaxel + thiotepa + topotecan + stem cell transplantation
Product Description
Mechanism of Action
R&D Progress
Filgrastim + Carboplatin + Etoposide phosphate + Paclitaxel + Thiotepa + Topotecan hydrochloride
Product Description
Mechanism of Action
R&D Progress
Filgrastim + Carboplatin + Etoposide phosphate + Paclitaxel + Thiotepa + Topotecan hydrochloride
Product Description
Mechanism of Action
R&D Progress
Filgrastim + Carmustine + Cisplatin + Cyclophosphamide + Etoposide + Thiotepa
Product Description
Mechanism of Action
R&D Progress
Filgrastim + Carmustine + Cisplatin + Cyclophosphamide + Etoposide + Thiotepa
Product Description
Mechanism of Action
R&D Progress
Filgrastim + CMF regimen + Carboplatin + Cyclophosphamide + Docetaxel + Doxorubicin + Etoposide + Fluorouracil + Ifosfamide + Methotrexate + Thiotepa + Stem cell transplantation
Product Description
Mechanism of Action
R&D Progress
filgrastim + CMF regimen + carboplatin + cyclophosphamide + docetaxel + doxorubicin hydrochloride + etoposide + fluorouracil + ifosfamide + methotrexate + thiotepa
Product Description
Mechanism of Action
R&D Progress
filgrastim + CMF regimen + carboplatin + cyclophosphamide + docetaxel + doxorubicin hydrochloride + etoposide + fluorouracil + ifosfamide + methotrexate + thiotepa
Product Description
Mechanism of Action
R&D Progress
filgrastim + recombinant interferon alfa + sargramostim + busulfan + cyclophosphamide + melphalan
Product Description
Mechanism of Action
R&D Progress
Filgrastim + Recombinant Interferon Alfa + Sargramostim + Busulfan + Cyclophosphamide + Melphalan + Autologous Hematopoietic Stem Cell
Product Description
Mechanism of Action
R&D Progress
filgrastim + recombinant interferon gamma + busulfan + cyclophosphamide + cyclosporine + cytarabine + idarubicin
Product Description
Mechanism of Action
R&D Progress
filgrastim + recombinant interferon gamma + busulfan + cyclophosphamide + cyclosporine + cytarabine + idarubicin
Product Description
Mechanism of Action
R&D Progress
filgrastim + recombinant interferon gamma + busulfan + cyclophosphamide + cyclosporine + cytarabine + idarubicin + stem cell transplantation
Product Description
Mechanism of Action
R&D Progress
filgrastim + sargramostim + cyclophosphamide + thiotepa
Product Description
Mechanism of Action
R&D Progress
filgrastim + sargramostim + cyclophosphamide + thiotepa
Product Description
Mechanism of Action
R&D Progress
flutamide + leuprolide + radiation therapy
Product Description
Mechanism of Action
R&D Progress
Gemcitabine + Carboplatin for Non-Small Cell Lung Cancer (Herbert Irving Comprehensive Cancer Center
Product Description
Mechanism of Action
R&D Progress
Gemcitabine + Cisplatin for Non-Small Cell Lung Cancer (Herbert Irving Comprehensive Cancer Center)
Product Description
Mechanism of Action
R&D Progress
Interferon Alfa 2B + Thalidomide
Product Description
Mechanism of Action
R&D Progress
Interferon Alfa 2B + Thalidomide
Product Description
Mechanism of Action
R&D Progress
Irinotecan Hydrochloride
Product Description
Mechanism of Action
R&D Progress
Melphalan + Autologous Stem Cell Transplantation
Product Description
Mechanism of Action
R&D Progress
Recombinant interferon gamma + Cisplatin + Doxorubicin hydrochloride + Gemcitabine hydrochloride + Mitomycin C + Radiation theraphy
Product Description
Mechanism of Action
R&D Progress
Taxotere + Estramustine
Product Description
Mechanism of Action
R&D Progress
temozolomide + thalidomide
Product Description
Mechanism of Action
R&D Progress
Temozolomide for Malignant Glioma(Herbert Irving Comprehensive Cancer Center)
Product Description
Mechanism of Action
R&D Progress
Thiotepa + Stem Cell Transplantation
Product Description
Mechanism of Action
R&D Progress
Topotecan + Taxol + Filgrastim
Product Description
Mechanism of Action
R&D Progress
Docetaxel + Estramustine + Mitoxantrone + Prednisone
Product Description
Mechanism of Action
R&D Progress
Filgrastim
Product Description
Mechanism of Action
R&D Progress
Intra Lesional rV-Tricom Vaccine
Product Description
Mechanism of Action
R&D Progress
MAGE-10.A2 + MART-1 antigen + NY-ESO-1 peptide vaccine + Tyrosinase Peptide
Product Description
Mechanism of Action
R&D Progress
MAGE-10.A2 + MART-1 Antigen + NY-ESO-1 Peptide Vaccine + Tyrosinase Peptide + Sargramostim
Product Description
Mechanism of Action
R&D Progress
NY-ESO-1 Peptide Vaccine + Sargramostim
Product Description
Mechanism of Action
R&D Progress
Recombinant Fowlpox-B7.1 Vaccine
Product Description
Mechanism of Action
R&D Progress
Recombinant Fowlpox-TRICOM Vaccine
Product Description
Mechanism of Action
R&D Progress
Recombinant vaccinia-Tricom vaccine
Product Description
Mechanism of Action
R&D Progress
topotecan
Product Description
Mechanism of Action
R&D Progress
Herbert Irving Comprehensive Cancer Center – Pipeline Analysis
Herbert Irving Comprehensive Cancer Center – Pipeline Products by Therapeutic Class
Herbert Irving Comprehensive Cancer Center Pipeline Products By Target
Herbert Irving Comprehensive Cancer Center – Pipeline Products by Route of Administration
Herbert Irving Comprehensive Cancer Center – Pipeline Products by Molecule Type
Herbert Irving Comprehensive Cancer Center - Dormant Projects
Herbert Irving Comprehensive Cancer Center – Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

Note: Product cover images may vary from those shown

RELATED PRODUCTS